PRPH ProPhase Labs Inc

ProPhase Labs to Provide COVID-19 Testing for Oyster Bay Township in New York

ProPhase Labs to Provide COVID-19 Testing for Oyster Bay Township in New York

ProPhase Labs Will Offer State-Of-The-Art Testing to Aid Oyster Bay Community in Reopening

GARDEN CITY, NY, April 22, 2021 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: PRPH), a diversified medical science and technology company, today announced that it has been awarded and signed a contract with The Town of Oyster Bay, New York, to provide reliable COVID-19 testing. The contract was awarded after a competitive process where ProPhase Labs demonstrated its COVID-19 testing capabilities, including its accurate and reliable test offerings and fast turnaround times. The Oyster Bay Township, located in Nassau County, encompasses 36 villages and hamlets and nearly 300,000 residents.

This partnership will help bring COVID-19 testing to thousands of Oyster Bay residents, ensuring a safe and controlled reopening for the township. The Town of Oyster Bay will offer ProPhase Labs’ saliva-based, viral RT-PCR multiplex-testing, a type of test proven to quickly detect and identify COVID-19 and any of its 17+ current viral mutations. With labs in both Garden City, New York and Old Bridge, New Jersey, ProPhase Labs has the capacity to provide test results to individuals within 24 hours from the time when one of its labs receives and accepts a specimen.

“We are incredibly happy to partner with The Town of Oyster Bay in their tremendous efforts to combat this virus and get residents back to ‘normal life’,” said Ted Karkus CEO of ProPhase Labs. “The Town of Oyster Bay joins the growing list of healthcare providers, organizations and municipalities that have selected ProPhase Labs for their COVID-19 testing needs. Our fast turnaround times and dependable testing solutions continue to be reasons why ProPhase Labs is selected as a testing partner.”

The roll out will begin with a focus on testing for school students and faculty. ProPhase Labs will also provide testing for major school events this year, such as graduations, proms, and homecomings. Additionally, testing will be offered to municipal employees and the general public in the weeks ahead.

Oyster Bay Town Supervisor Joseph Saladino stated, “The Oyster Bay Town Board recently retained the services of ProPhase Labs with the goal of helping our residents get back to the things they enjoy most in life. From graduation ceremonies to classroom activities and athletic fields, the Town of Oyster Bay is first committed to helping students get back to normal as quickly as possible. In the coming weeks, we will expand eligibility to all residents so that families and seniors looking to attend a concert, dance at a wedding or simply get on a flight, can do so easily by accessing non-invasive COVID testing and obtain quick results.”

About ProPhase Labs

ProPhase Labs (NASDAQ: PRPH) is a diversified medical science and technology company. The Company’s laboratory testing subsidiary, ProPhase Diagnostics, offers SARS-CoV-2 (COVID-19) and COVID-19 viral mutation PCR tests through both saliva and nasal swab methods at its CLIA certified laboratories. ProPhase Diagnostics also provides Respiratory Pathogen Panel (RPP) Molecular tests including Influenza A and B and others. ProPhase Labs researches, develops, manufactures, distributes, markets and sells OTC consumer healthcare products and dietary supplements, including dietary supplements under the TK Supplements® brand. The Company actively pursues strategic investments and acquisition opportunities for other companies, technologies and products. For more information, visit .

Investor Contact

Chris Tyson

Managing Director

MZ Group - MZ North America

949-491-8235



Media Contact:

5W Public Relations

212-999-5585



EN
22/04/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ProPhase Labs Inc

 PRESS RELEASE

ProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-...

ProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-Smart™ and Advances Crown Medical Collections Initiative Each Initiative Has the Potential to Drive Significant Liquidity and Strengthen the Company’s Balance Sheet UNIONDALE, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and consumer products company, today announced that it has initiated a potential sale or strategic partnership process for BE-Smart™, its clinically validated esophageal cancer risk stratification test, and is a...

 PRESS RELEASE

Join ProPhase Labs’ Exclusive Live Investor Webinar and Q&A Session on...

Join ProPhase Labs’ Exclusive Live Investor Webinar and Q&A Session on February 3rd UNIONDALE, NY, Feb. 02, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) (“ProPhase” or the “Company”) is pleased to invite investors to a webinar on Tuesday, February 3, 2026, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature ProPhase Labs Chairman and CEO Ted Karkus. Attendees will gain an in-depth look at ProPhase’s dynamic portfolio of high-growth healthcare assets spanning molecular diagnostics, genomics, and consumer health. Karkus will highlight recent mileston...

 PRESS RELEASE

ProPhase Labs Provides Crown Medical Collections Update; 250+ Insuranc...

ProPhase Labs Provides Crown Medical Collections Update; 250+ Insurance Payors Engaged, Approximately 50 Matters in Advanced Settlement Posture UNIONDALE, NY, Jan. 26, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and consumer products company, today provided an operational update on the progress of its Crown Medical Collections initiative relating to legacy COVID-19 testing receivables held by its laboratory subsidiaries currently in Chapter 11 proceedings. Crown Medical Collections (“Crown Medical”), which se...

 PRESS RELEASE

ProPhase Labs Uplists from Pink Sheets to OTC Market

ProPhase Labs Uplists from Pink Sheets to OTC Market UNIONDALE, NY, Jan. 22, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (“ProPhase” or the “Company”), a diversified life sciences and diagnostics company, today announced that its common stock has been approved and uplisted from the Pink Sheets to the OTC market. “We are pleased to have completed this uplisting from the Pink Sheets to the OTC market,” said Ted Karkus, Chairman and Chief Executive Officer of ProPhase Labs. “We believe the coming weeks will mark an important inflection point for ProPhase Labs. We continue to see encouragin...

 PRESS RELEASE

ProPhase Labs Provides Update on Convertible Debt Conversions, Capital...

ProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset Value UNIONDALE, NY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) today provided an update to shareholders regarding recent trading activity, its capital structure, and the Company’s underlying asset base. The Company believes that recent volatility in its stock price has been driven by a combination of short-term technical factors, including the accelerated conversion and resale of a significant portion of its outstanding convertible debt, the completion of a 1-f...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch